MGMT and glioblastoma: The meta-analysis encouraged the mandatory testing of MGMT promoter status in routine practice in elderly glioblastoma patients due to the observation of a strong predictive but not prognostic value of this biomarker to TMZ chemotherapy and a direct association between MGMT testing and individual treatment choice.